API moves to buy SILK Laser for $169M

Board of 140-plus non-surgical aesthetics clinic chain supports deal Australian Pharmaceutical Industries (API) has entered into an transaction process agreement with non-surgical aesthetics outfit SILK Laser Australia to acquire 100% of its outstanding shares $3.15 per share. Wesfarmers, of which API is now a wholly-owned subsidiary, has entered a transaction process deed with SILK Laser